Antibiotic Trial Network Could Emerge From FDA/NIH Workshop
This article was originally published in The Pink Sheet Daily
Master trial protocols aimed at a patients with resistant organisms could streamline product development once sponsors are ready to “pay to play.”
You may also be interested in...
Sponsors say the large number of biomarkers that will be searched for in candidates for the lung cancer trial should allow researchers to find patients much faster, and will offer cost-savings over traditional drug development.
Five-point plan that calls for FDA to change definition of ‘labeling’ and ‘substantial evidence’ may offer hints as to what the next iteration of 21st Century Cures legislation will offer.
Breast cancer meeting highlights challenges of patient-focused drug development as breast cancer patients ask for trials to better identify characteristics of super-responders so patients can make more informed risk-benefit decisions.